Structural Heart & Transcatheter Valves

Technology Definition and Deployment Classes

Transcatheter heart valves are collapsible valve prostheses delivered by catheter, typically transfemoral or transapical, to replace or repair a failing native cardiac valve without full sternotomy/cardiopulmonary bypass.

Two dominant deployment classes are:

• Balloon-expandable valves — e.g., Edwards SAPIEN platform. The manufacturer describes the SAPIEN 3 Ultra RESILIA as a balloon-expandable valve with bovine pericardial leaflets and a RESILIA anti-calcification treatment \(Tier 2, self-reported\).
• Self-expanding valves — e.g., Medtronic Evolut/CoreValve platform. Medtronic describes Evolut FX as a self-expanding nitinol-frame valve with bovine pericardial leaflets \(Tier 2, self-reported\).

The foundational recorded claim for a collapsible valve delivered by catheter is a granted patent:

• US 5,411,552 A — “Valve prosthesis for implantation in the body and a catheter for implanting such valve prosthesis” — granted 1995-05-02 \(Tier 1, granted patent\).

This patent is evidence of recorded claims, not proof of clinical performance or current commercial viability. It is now expired.

Clinical Evidence

Key peer-reviewed evidence:

• PARTNER B — Leon et al., NEJM 2010

In patients with severe aortic stenosis who could not undergo surgery, transcatheter aortic valve replacement (TAVR) reduced 1-year all-cause mortality to 30.7% vs 50.7% with standard therapy \(Tier 1, peer-reviewed, DOI 10.1056/NEJMoa1008232\).

This was the pivotal proof that TAVR creates survival benefit in an otherwise untreated population.

• PARTNER 3 — Mack et al., NEJM 2019

In low-risk surgical candidates, TAVR with a balloon-expandable valve was non-inferior, and on the primary composite endpoint of death, stroke, or rehospitalization at 1 year was 8.5% vs 15.1% for surgery \(Tier 1, peer-reviewed, DOI 10.1056/NEJMoa1814052\).

• Evolut Low Risk — Popma et al., NEJM 2019

A self-expanding valve was non-inferior to surgery in low-risk patients on the primary 2-year composite endpoint \(Tier 1, peer-reviewed, DOI 10.1056/NEJMoa1816885\).

These trials underpin expansion from inoperable → high-risk → intermediate-risk → low-risk patients.

Regulatory and Standards Context

The field is regulated as Class III cardiovascular implantable devices. For example, transcatheter heart valves are assessed under ISO 5840-3:2021 — Cardiovascular implants — Cardiac valve prostheses — Part 3: Heart valve substitutes implanted by transcatheter techniques \(Tier 1, standards body\).

This standard addresses in vitro hydrodynamic performance, fatigue, durability, and preclinical evaluation. It is a technical requirement, but compliance with ISO 5840 does not by itself prove long-term clinical durability.

IP and Patent Status

• Granted patent used above: US 5,411,552 A, granted 1995-05-02 \(Tier 1\).

Class: granted patent, not application.

What it can support: evidence that collapsible catheter-delivered valve concepts were recorded in the patent system.

What it cannot support: current commercial dominance, freedom to operate, or performance.

• Patent applications vs granted patents

None of the technical/performance claims in this note rely on patent applications. Only the granted patent above is used for IP evidence.

• Current freedom-to-operate / patent walls

The current major device families are protected by later patent families, not by the expired 1995 patent. Detailed FTO analysis requires a separate current patent search \([needs primary source validation]\) if used for investment decisions.

Cross-Reference: Marketing Claims vs SEC Filings

This is a necessary check because company product pages are self-reported and often use selected trial summaries.

• Medtronic’s product page markets Evolut FX as having “excellent hemodynamics” and “proven design” \(Tier 2, self-reported\).

The Medtronic SEC 10-K filing index \(SEC EDGAR, CIK 0000064670\) contains risk factors warning that clinical trial results may not predict real-world outcomes, and that products face regulatory, pricing, and competitive risks.

• Edwards’ product page markets SAPIEN 3 Ultra RESILIA with low-risk trial support and anti-calcification claims \(Tier 2, self-reported\).

Edwards’ 10-K filing index \(SEC EDGAR, CIK 0001099800\) contains risk factors about competition, concentration of revenue in structural heart products, clinical uncertainty, and hospital staffing/capacity constraints.

Observed discrepancy: There is no hard numerical contradiction found in the sources above, but there is a reporting asymmetry: product pages present selected trial benefits without equivalent prominence for stroke/pacemaker risks, while 10-K filings emphasize that clinical results and adoption are uncertain and subject to competitive/payer pressure. For technical claims, treat company product pages as one lineage, not independent corroboration.

Quantitative Worked Calculation: Post-TAVR Effective Orifice Area via Gorlin Formula

The Gorlin equation is a standard hemodynamic method used in valve assessment.

Formula

\[

EOA = \frac{CO\ (mL/min)}{44.3 \times HR\ (bpm) \times SEP\ (s/beat) \times \sqrt{\Delta P\ (mmHg)}}

\]

Where:

• \(EOA\) = effective orifice area in cm²
• \(CO\) = cardiac output in mL/min
• \(HR\) = heart rate in beats/minute
• \(SEP\) = systolic ejection period in seconds/beat
• \(\Delta P\) = mean transvalvular pressure gradient in mmHg
• 44.3 = unit conversion constant derived from \( \sqrt{2g} \) and mmHg-to-cmH₂O conversion

Inputs

Calculation

\[

EOA = \frac{5000}{44.3 \times 70 \times 0.35 \times \sqrt{10}}

\]

\[

EOA = \frac{5000}{44.3 \times 24.5 \times 3.1623}

\]

\[

EOA = \frac{5000}{3432.5}

\]

\[

EOA \approx 1.46\ \text{cm}^2

\]

Sensitivity

Interpretation: A derived EOA of ~1.46 cm² is consistent with post-TAVR relief of severe aortic stenosis, but it is not a clinical outcome by itself. It depends on assumed resting CO, HR, and SEP.

Parameter Table

Unit economics / business model

• Who monetizes: Medtronic, Edwards Lifesciences, Boston Scientific, Abbott, and other structural heart device makers monetize via single-use disposable valve-and-delivery-system sales to hospitals.
• How they monetize: Per-procedure device sale, not a subscription/royalty model at the point of care. There may be hospital bundle contracts, but the core is unit pricing per valve system.
• Who captures value: Device manufacturers capture the direct product margin; hospitals capture procedure reimbursement under CMS MS-DRG payment for endovascular cardiac valve replacement.
• Typical margins: Structural heart transcatheter valves are generally described as high-margin medical devices, but the exact current gross-margin figures must be pulled from each company’s 10-K line-item disclosures; any specific percentage cited without that extraction is [needs primary source validation].
• Evidence for business model: Product-line disclosures appear in Medtronic and Edwards SEC 10-K filing indexes \(Medtronic EDGAR, Edwards EDGAR\).

Disconfirming Evidence

The structural heart transcatheter valve thesis would be weakened or invalidated if:

1. Long-term durability fails: If 10-year data show higher structural valve degeneration or reintervention vs surgery, the low-risk expansion thesis fails.
2. Stroke/pacemaker rates do not improve: If next-generation devices cannot reduce paravalvular leak, stroke, or permanent pacemaker rates, real-world adoption and guidelines could stall.
3. Payer/reimbursement reverses: If CMS or major commercial payers narrow coverage for low-risk TAVR or demand long-term cost-effectiveness evidence not yet available, hospital volume growth would decelerate.
4. Competitive/price destruction: If multiple me-too valves compress hospital ASPs faster than unit growth, the high-margin device model weakens.
5. Manufacturing/quality failure: A recall or fatigue-fracture signal in nitinol frames or leaflet calcification would directly challenge the self-reported durability claims.

Recent developments

• 2026-09-10 — CMS finalizes an updated TAVR National Coverage Determination (NCD).

CMS finalized the reconsidered NCD for transcatheter aortic valve replacement (TAVR),

removing the Coverage with Evidence Development (CED) requirement for patients with

symptomatic severe aortic stenosis (CED retained for the broader/other indications).

The updated NCD was issued September 10, 2026, following a ~nine-month review that CMS

initiated in December 2025 after accepting Edwards Lifesciences' request, and a 2026

proposed decision. This is a regulatory/reimbursement change that widens covered access

for the incumbent TAVR franchises (Edwards Lifesciences, EW; Medtronic, MDT) and for

Boston Scientific's (BSX) re-entry path — material to the payer/volume leg of this thesis.

Sources:

• CMS — Aortic Valve Replacement / updated NCD page (updated NCD issued 2026-09-10): cms.gov
• CMS — TAVR NCD decision memo (NCAId=321): cms.gov
• ACC — "CMS Finalizes Updated TAVR National Coverage Determination" (2026-09-15): acc.org
• STS — "CMS Finalizes Updated NCD for TAVR Following Nine-Month Review": sts.org

Original scope and definitions

Transcatheter structural heart interventions — replacing or repairing heart valves through catheters instead of open-heart surgery. The core technology: a collapsible tissue valve mounted on a stent frame, crimped onto a delivery catheter, threaded through the femoral artery or transseptal puncture, and expanded at the target valve. TAVR (transcatheter aortic valve replacement) is the dominant category — a $7B+ market growing 10–15% annually. TEER (transcatheter edge-to-edge repair), TMVR (mitral replacement), and TTVR (tricuspid replacement) are the expansion frontiers.

Operating constraints

Why it's a moat — clinical trials, regulatory barriers, and installed-base lock-in

The PMA barrier: Structural heart devices require FDA Premarket Approval (PMA) — the highest regulatory hurdle in medtech. A PMA requires a randomized controlled trial (RCT) against surgery or best medical therapy, typically enrolling 500–2,000+ patients with multi-year follow-up. The PARTNER 3 trial (Edwards) enrolled 1,000 low-risk patients and just reported 7-year follow-up data at NY Valves 2026. The Evolut Low Risk trial (Medtronic) is at 6-year follow-up. A new entrant would need to run a similar trial — 7–10 years and $100M+ — against moving benchmarks. This is the deepest moat in medtech.

Durability is the battleground: As TAVR expands to younger patients (50–65 years), valve durability becomes the deciding factor. A surgical bioprosthetic valve lasts 10–15 years; TAVR valves must match or exceed this. The 7-year PARTNER 3 data showed SAPIEN 3 had comparable structural valve deterioration and reintervention rates vs. surgery — valves were holding up. Medtronic's CoreValve/Evolut platform at 8 years showed <3% reintervention. But differences are emerging: balloon-expandable (SAPIEN) may have advantages in coronary access for future procedures and lower permanent pacemaker rates; self-expanding (Evolut) may have larger effective orifice areas. These trade-offs create surgeon preference — and switching costs.

Lifetime management lock-in: A 55-year-old TAVR patient will likely need a second valve in 15–20 years. The second procedure is often a valve-in-valve TAVR (placing a new valve inside the old one) — and the new valve must be compatible with the old frame. Edwards' larger installed base (60%+ share in US TAVR) means more patients will return for Edwards-on-Edwards procedures. This is the installed-base flywheel: every valve placed today is a future valve-in-valve customer.

Mitral and tricuspid — the next wave: The mitral valve market is larger than aortic (more patients with mitral regurgitation) but technically harder — the mitral annulus is D-shaped, dynamic, and surrounded by critical structures (left ventricular outflow tract). Edwards' SAPIEN M3 (transseptal TMVR) just reported positive 1-year outcomes in MAC (mitral annular calcification) — a patient population with no surgical option. Tricuspid is even earlier — EVOQUE is the first approved TTVR device, with a market that could rival TAVR in volume over 10–15 years.